China's biopharma pipeline has grown to over 18,000 active assets, with ~17,500 classified as innovative. Oncology accounts for ~9,950 programs, but seven additional therapeutic areas each exceed 1,000. Post-2015 NMPA reforms drove the expansion, producing ~2,300 innovative IND applications accepted in 2023 alone.

Only ~510 assets have reached Phase III. The pipeline is mid-stage heavy, signaling a wave of readouts rather than near-term commercial pressure. When filtered to late-stage innovative assets (Phase II+), the count drops to ~2,300, and I&I overtakes oncology as the largest category at ~830 assets.

China originates roughly half of global innovation in 11 modalities. Bispecifics, ADCs, CAR-T, and PROTACs each show ~50% China share in global pools of ~1,000+ assets. Gene therapy at ~20% and antisense at ~15% represent genuine white space where China's structural advantages have not translated. Five of seven example white-space targets are CNS receptors requiring Western trial infrastructure.

335 out-licensing deals to the US and Europe since 2021, with deal volume growing ~5.6x and upfronts ~7x over that period. The buyer pool expanded from 17 specialty firms to 84 companies including all Top 20 Western pharma. AstraZeneca leads with 17 deals totaling ~$42B. GSK, Merck, Novartis, and Eli Lilly cluster at 8-9 deals and $14-20B each.

The seller market is fragmented across ~177 unique companies, with the top 10 accounting for just ~25% of deals. Only ~21% of deals occur between repeat seller-buyer pairs. Biocytogen leads at 21 deals, followed by Hengrui at 11.

~1 in 5 Chinese assets have US presence at Phase I, but only ~1 in 30 reach US approval. ~39% of the translation barriers trace to BIOSECURE-style policy risk. The sharpest drop occurs from Phase III to Approved, where CMC readiness and evidence acceptance become hard gates.

ADCs spread across ~150 targets with no single target exceeding ~10% of the ~865 China-origin pipeline. Topo I inhibitors have overtaken MMAE as the dominant payload at 46% versus 29%. CLDN18.2 shows the highest Phase III conversion rate among top targets.

China's ~900 bispecifics cluster into three competitive mechanisms: targeted combos (EGFR + c-Met dominates at 33 of 55 programs), checkpoint/IO combos, and CD3 T-cell engagers. Unlike ADCs, bispecifics show real non-oncology depth, with autoimmune programs at 94% preclinical representing a forming wave.

Cell and gene therapy is China's most therapeutically diverse modality. Hospital-based CAR-T manufacturing gives China first-mover position in autoimmune indications, with 71 SLE programs, 47 systemic sclerosis, and 27 ANCA-associated vasculitis. ~160 academic hospitals originate 35-40% of the CGT pipeline. Gene therapy remains a white space at ~20% China share versus ~45-50% for cell therapy.